Cephalon On Track To File Treanda For Second Cancer Indication By Year-End
This article was originally published in The Pink Sheet Daily
Executive Summary
Bendamustine meets both primary endpoints in Phase III for relapsed, rituximab-refractory non-Hodgkin’s lymphoma.
You may also be interested in...
Cephalon Files Treanda For NHL Indication
Chemotherapeutic has been granted a priority review for an earlier filing, for treatment of chronic lymphocytic leukemia.
Cephalon Files Treanda For NHL Indication
Chemotherapeutic has been granted a priority review for an earlier filing, for treatment of chronic lymphocytic leukemia.
Cephalon Files Treanda For Chronic Lymphocytic Leukemia
Submission represents a milestone for Cephalon’s oncology program, firm says.